Ligustilide could change the immunosuppressive function of cancer-associated fibroblasts (CAFs) through the TLR4-NF-κB pathway and restore T-cell proliferation previously inhibited by the CAF supernatant (Ma et al., 2019). Here, TLR4 is linked to cancer.